Abstract
It has long been recognized that the central nervous system (CNS) exhibits only limited capacity for axonal regeneration following injury. It has been proposed that myelin-associated inhibitory molecules are responsible for the nonpermissive nature of the CNS environment to axonal regeneration. Experimental strategies to enhance regeneration by neutralizing these inhibitory molecules are rapidly advancing toward clinical application. It is therefore important that the physiological distribution and functions of these supposed inhibitory molecules should be understood. In this review, we examine the distribution of these inhibitors of neurite outgrowth in relation to the longitudinal polarization of the myelinated axon into the node of Ranvier and associated domains and explore their potential domain specific physiological functions. Potential implications for the therapeutic strategy of neutralizing these inhibitory molecules to promote neural repair are discussed.
Keywords: myelin-associated glycoprotein, oligodendrocyte precursor cells, peripheral nervous system, myelinated axons, TN-R knockout mice
Current Pharmaceutical Design
Title: Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors
Volume: 13 Issue: 24
Author(s): Quan-Hong Ma, Wu-Lin Yang, Du-Yu Nie, Gavin S. Dawe and Zhi-Cheng Xiao
Affiliation:
Keywords: myelin-associated glycoprotein, oligodendrocyte precursor cells, peripheral nervous system, myelinated axons, TN-R knockout mice
Abstract: It has long been recognized that the central nervous system (CNS) exhibits only limited capacity for axonal regeneration following injury. It has been proposed that myelin-associated inhibitory molecules are responsible for the nonpermissive nature of the CNS environment to axonal regeneration. Experimental strategies to enhance regeneration by neutralizing these inhibitory molecules are rapidly advancing toward clinical application. It is therefore important that the physiological distribution and functions of these supposed inhibitory molecules should be understood. In this review, we examine the distribution of these inhibitors of neurite outgrowth in relation to the longitudinal polarization of the myelinated axon into the node of Ranvier and associated domains and explore their potential domain specific physiological functions. Potential implications for the therapeutic strategy of neutralizing these inhibitory molecules to promote neural repair are discussed.
Export Options
About this article
Cite this article as:
Quan-Hong Ma , Wu-Lin Yang , Du-Yu Nie , Gavin S. Dawe and Zhi-Cheng Xiao , Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368602
DOI https://dx.doi.org/10.2174/138161207781368602 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and Two Iodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere Human Brain Slices
Current Radiopharmaceuticals Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets C-Methionine PET/CT in Central Nervous System Tumours: A Review
Current Radiopharmaceuticals Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
Current Radiopharmaceuticals